PMGC Holdings (ELAB) Change in Account Payables (2022 - 2026)
PMGC Holdings (ELAB) posted Change in Account Payables of -$2928.0 for Q1 2026, up 99.26% sequentially from -$397728.0 in Q1 2025, and up 99.26% YoY from -$1469.4 in Q1 2025.
PMGC Holdings (ELAB) Change in Account Payables (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Change in Account Payables for 5 years, with the latest figure at -$2928.0 in Q1 2026.
- Quarterly Change in Account Payables rose 99.26% year-over-year to -$2928.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2928.0 (down 289.51% YoY) and the FY2025 annual result came in at -$397728.0, down 200.0% from the prior year.
- Change in Account Payables rose to -$2928.0 in Q1 2026 per ELAB's latest filing, from -$397728.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $5.9 million in Q4 2022 and troughed at -$397728.0 in Q1 2025.
- A 5-year average of $524885.8 and a median of $436.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2024 and 2025: Change in Account Payables soared 11792.43% in 2024, then tumbled 25642.91% in 2025.
- Over 5 years, Change in Account Payables stood at $5.9 million in 2022, then plunged by 102.8% to -$165200.0 in 2023, then jumped by 215.55% to $190895.0 in 2024, then slumped by 308.35% to -$397728.0 in 2025, then surged by 99.26% to -$2928.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$2928.0, -$397728.0, and $190895.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | -7,862.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,928.00 |
| Mar 31, 2026 | -2,928.00 |
| Mar 31, 2025 | -397,728.00 |
| Mar 31, 2025 | -397,728.00 |
| Dec 31, 2024 | 190,895.00 |
| Dec 31, 2024 | 190,895.00 |
| Sep 30, 2024 | 156,527.00 |
| Sep 30, 2024 | 156,527.00 |
| Jun 30, 2024 | 51,851.00 |
| Jun 30, 2024 | 51,851.00 |
| Mar 31, 2024 | -1,545.00 |
| Mar 31, 2024 | -1,545.00 |
| Dec 31, 2023 | -165,200.00 |
| Dec 31, 2023 | -165,200.00 |
| Sep 30, 2023 | -15,319.00 |
| Sep 30, 2023 | -15,319.00 |
| Jun 30, 2023 | 436.00 |
| Jun 30, 2023 | 436.00 |
| Mar 31, 2023 | 59,564.00 |
| Mar 31, 2023 | 59,564.00 |